Diagnostic value of tumor marker pro-gastrin-releasing peptide in patients with small cell lung cancer: A systematic review

Chinese Medical Journal

Volumn 124, Issue 10, 2011, Pages 1563-1568

  Tang, Jian hua ^a   Zhang, Xiu long ^a   Zhang, Zhi hua ^a   Wang, Rui ^b   Zhang, He ming ^a   Zhang, Zhi lin ^a   Wang, Jing hui ^a   Ren, Wei dong ^a  

^a First Affiliated Hospital of Hebei Northern College   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Meta analysis; ProGRP31 98; Small cell lung cancer; Tumor marker

Indexed keywords

PROGASTRIN RELEASING PEPTIDE[31-98];

ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LUNG SMALL CELL CANCER; META ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; STANDARD; SYSTEMATIC REVIEW;

HUMANS; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; SENSITIVITY AND SPECIFICITY; SMALL CELL LUNG CARCINOMA;

EID: 79957537458     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.10.023     Document Type: Article

References (34)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. McDonald TJ, Nilsson G, Vagne M, Ghatei M, Bloom SR, Mutt V. A gastrin-releasing peptide from the porcine non-antral gastric tissue. Gut 1978; 19: 767-774.
3. Yamaguchi K, Abe K, Adachi I, Kimura S, Suzuki M, Shimada A, et al. Peptide hormone production in primary lung tumors. Recent Results Cancer Res 1985; 99: 107-116.
4. Yamaguchi K, Abe K, Adachi I, Otsubo K, Nagasaki K, Suzuki M, et al. Peptide hormone production in small cell lung carcinomas with particular reference to gastrin-releasing peptide. Jpn J Clin Oncol 1986; 16: 235-241.
5. Berendsen HH, De Leij L, Poppema S, Postmus PE, Boes A, Sluiter HJ, et al. Clinical characterization of non-small-cell- lung cancer. Tumors showing neuroendocrine differentiation features. J Clin Oncol 1989; 7: 1614-1620.
6. Yamaguchi K, Abe K, Kameya T, Adachi I, Taguchi S, Otsubo K, et al. Production and molecular size heterogeneity of immunoreactive gastrin-releasing peptide in fetal and adult lungs and primary lung tumors. Cancer Res 1983; 43: 3932-3939.
7. McDonald TJ, Nilsson G, Vagne M, Ghatei M, Bloom SR, Mutt V. A gastrin releasing peptide from the porcine nonantral gastric tissue. Gut 1978; 19: 767-774.
8. Opemek GM, Sapoutzis N. Pro-Gastrin-releasing Peptide (Pro-GRP), a tumor marker for small cell lung cancer. Anticancer Res 2003; 23: 895-898.
9. Goto K, Kodama T, Hojo F, Kubota K, Kakinuma R, Matsumoto T, et al. Clinicopathologic characteristics of patients with non small cell lung carcinoma with elevated serum progastrin-releasing peptide levels. Cancer 1998; 82: 1056-1061.
10. Liu GJ, Wu TX. The statistical process of meta-analysis modern rehabilitation. Chin J Evid-based Med (Chin) 2003; 7: 538-539.
11. Liu GJ, Wu TX. Clinical implementation of Forest plots in meta-analysis. Chin J Evid Based Med (Chin) 2004; 4: 198-201.
12. Liu GJ, Wu TX. Summary ROC curve-diagnostic test method of meta-analysis. Chin J Evid Based Med (Chin) 2003; 3: 41-44.
13. Katsumi A, Yoshio M, Kenichi U, Tomiko K, Akira H, Tetsuro K, et al. Enzyme immunoassay of immunoreactive progastrin-releasing peptide (31-98) as tumor marker for small-cell lung carcinoma: development and evaluation. Clin Chem 1995; 41: 537-543.
14. Ken Y, Katsumi A, Ken-ichi U, Toyoharn F, Noboru M, Shigehiro Y, et al. Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement. Jpn J Cancer Res 1995; 86: 698-705.
15. Takada M, Kusunoki Y, Masuda N, Matui K, Yana T, Ushijima S, et al. Pro-gatrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase. Brit J Cancer 1996; 73: 1227-1232.
16. Takuji O, Kenji E, Takashi K, Takayasu K, Nobuyuki Y, Yuichiro O, et al. Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. Clin Cancer Res 1997; 3: 123-128.
17. Koichi G, Tetsuro K, Fumihiko H, Kaoru K, Ryutaro K, Taketoshi M, et al. Clinicopathologic characteristics of patients with nonsmall cell lung carcinoma with elevated serum progastrin-releasing peptide levels. Cancer 1998; 82: 1056-1061.
18. Stieber P, Dienemann H, Schalhorn A, Schmitt UM, Reinmiedl J, Hofmann K, et al. Pro-gastrin-releasing peptide (ProGRP)-a useful marker in small cell lung carcinomas. Anticancer Res 1999; 19: 2673-2678.
19. Sunaga N, Tsuchiya S, Minato K, Watanabe S, Fueki N, Hoshino H, et al. Serum pro-gastrin-releasing peptide is a useful marker for treatment monitoring and survival in small-cell lung cancer. Oncology 1999; 57: 143-148.
20. Lamy PJ, Grenier J, Kramar A, Pujol JL. Pro-gastrin- releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer. Lung Cancer 2000; 29: 197-203.
21. Wu J, Yu FZ. Diagnosis value of tumor marker Pro-GRP in small cell lung cancer. Chin J Tuberc Respir Dis (Chin) 2000; 23: 570-571.
22. Xiong SG, Qu YE, Wang JX. Clinical value of tumor marker CEA, CYFRA 21-1, NSE and PROGRP in lung cancer. Clin Med China 2002; 18: 133-135.
23. Shibayama T, Ueoka H, Nishii K, Kiura K, Tabata M, Miyatake K, et al. Complementary roles of pro-gastrin- releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer 2001; 32: 61-69.
24. Li A, Yang J, Li X, Li R, Wang YL, Si LS. Diagnostic value of serum ProGRP 31-98 in patients with small cell lung cancer. Acad J Xi'an Jiaotong Univ 2003; 15: 44-46.
25. Yang L, Zhang Y, Ruan JZ, Shi GL, Li SY, Song CX. The value of Pro-GRP, NSE, CA125 and β2-MG in patients with SCLC. J Chin Pract Med 2003; 12: 19-22.
26. Opemek GM, Sapoutzis N. Pro-gastrin-releasing peptide (Pro-GRP), a tumor marker for small cell lung cancer. Anticancer Res 2003; 23: 895-898.
27. Xu LY, You YH, Zhu YZ, Liu Z. Relationship between the serum proGRP concentration and SCLC. Tuber Thor Tumor 2003; 4: 287-292.
28. Yu BX, Liu QF, Chen LG. A clinical study of ProGRP as a new tumor marker for small cell lung cancer. Chin J Lung Cancer (Chin) 2006; 6: 209-210.
29. Yan F, Hu XY, Xu X. Clinical significance of tumor marker serum Pro-GRP in lung cancer. Chin J Clin Lab Sci (Chin) 2004; 122: 447-448.
30. Molina R, Auge JM, Alicarte J, Filella X, Viñolas N, Ballesta AM. Pro-gastrin-releasing peptide in patients with benign and malignant diseases. Tumor Biol 2004; 25: 56-61.
31. Yang SY, Zhang WG, Sun XZ, Zhao XH, Zhu JH, Yang DC. Significance and correlation between serum proGRP and NSE in the early diagnosis of small cell lung cancer. J Xi'an Jiaotong Univ (Med Sci) 2005; 26: 247-249.
32. Sun J, Liu J, Yang BJ. The clinical value of serum pro-gastrin-releasing peptide and neuron-specific enolase for small-cell lung cancer. J Mod Lab Med 2005; 20: 11-13.
33. Yu WP, Wang WL, Huang JX, Jiang Y, Hong WY, Hou SZ, et al. A clinical study of serum progastrin releasing peptide in patients with small cell lung cancer. Heibei Med (Chin) 2006; 12: 703-704.
34. Jin X, Chen JK, Tong YL, Zuo XH, Huang Y, Yin XY, et al. Clinical significance of tumor marker ProGRP, NSE, CYFRA21-1 in lung cancer. Chin J Health Lab (Chin) 2007; 17: 1008-1009.